277 related articles for article (PubMed ID: 19404540)
41. Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency.
Bruno NE; Yano Y; Takei Y; Qin L; Suzuki T; Morser J; D'Alessandro-Gabazza CN; Mizoguchi A; Suzuki K; Taguchi O; Gabazza EC; Sumida Y
Thromb Haemost; 2008 Jul; 100(1):90-100. PubMed ID: 18612543
[TBL] [Abstract][Full Text] [Related]
42. Production and evaluation of recombinant hirudin.
Courtney M; Loison G; Lemoine Y; Riehl-Bellon N; Degryse E; Brown SW; Cazenave JP; Defreyn G; Delebassee D; Bernat A
Semin Thromb Hemost; 1989 Jul; 15(3):288-92. PubMed ID: 2688101
[TBL] [Abstract][Full Text] [Related]
43. Anticoagulant and antithrombotic actions of recombinant hirudin.
Kaiser B
Semin Thromb Hemost; 1991 Apr; 17(2):130-6. PubMed ID: 1837615
[No Abstract] [Full Text] [Related]
44. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plasmin interactions.
Nielsen VG
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):647-56. PubMed ID: 17890952
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological survey of recombinant hirudin.
Markwardt F; Fink G; Kaiser B; Klöcking HP; Nowak G; Richter M; Stürzebecher J
Pharmazie; 1988 Mar; 43(3):202-7. PubMed ID: 3380865
[TBL] [Abstract][Full Text] [Related]
46. [Research progress in hirudin fusion protein--review].
Zhang CL; Yu AP; Jin JD; Wu CT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):215-8. PubMed ID: 17490558
[TBL] [Abstract][Full Text] [Related]
47. Application of HPLC-ESI-ITMS in the quality control of carboxyterminal sequence confirmation for the recombinant DNA product Hirudin Variant 3.
Huang XD; Tong WW; Fan XL; Li ZH
J Pharm Biomed Anal; 2007 Jan; 43(2):533-9. PubMed ID: 17141443
[TBL] [Abstract][Full Text] [Related]
48. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
He S; Johnsson H; Zabczyk M; Hultenby K; Cao H; Blombäck M
Br J Haematol; 2013 Mar; 160(6):806-16. PubMed ID: 23360261
[TBL] [Abstract][Full Text] [Related]
49. Covalent linkage of streptokinase to recombinant hirudin: a novel thrombolytic agent with antithrombotic properties.
Phaneuf MD; Ozaki CK; Johnstone MT; Loza JP; Quist WC; LoGerfo FW
Thromb Haemost; 1994 Apr; 71(4):481-7. PubMed ID: 8052967
[TBL] [Abstract][Full Text] [Related]
50. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
[TBL] [Abstract][Full Text] [Related]
51. Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development.
Landskroner K; Olson N; Jesmok G
J Vasc Interv Radiol; 2005 Mar; 16(3):369-77. PubMed ID: 15758133
[TBL] [Abstract][Full Text] [Related]
52. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
53. Haemostyptic effects of batroxobin with regard to hirudin treatment.
Markwardt F; Kaiser B; Richter M
Thromb Res; 1992 Dec; 68(6):475-82. PubMed ID: 1341058
[TBL] [Abstract][Full Text] [Related]
54. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor.
Nielsen VG
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549
[TBL] [Abstract][Full Text] [Related]
55. Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes.
Meng M; Liu Y; Wang YB; Wang JC; Zhang H; Wang XQ; Zhang X; Lu WL; Zhang Q
J Control Release; 2008 Jun; 128(2):113-9. PubMed ID: 18423766
[TBL] [Abstract][Full Text] [Related]
56. Expression and purification of recombinant human serum albumin fusion protein with VEGF165b in Pichia pastoris.
Zhu RY; Xin X; Dai HY; Li Q; Lei JY; Chen Y; Jin J
Protein Expr Purif; 2012 Sep; 85(1):32-7. PubMed ID: 22750397
[TBL] [Abstract][Full Text] [Related]
57. Cloning and purification of an anti-thrombotic, chimeric Staphylokinase in Pichia pastoris.
Vandana ; Kantipudi S; Maheshwari N; Sharma S; Sahni G
Protein Expr Purif; 2019 Oct; 162():1-8. PubMed ID: 31108209
[TBL] [Abstract][Full Text] [Related]
58. Transcriptomic Analysis of the Influence of Methanol Assimilation on the Gene Expression in the Recombinant
Li T; Ma J; Xu Z; Wang S; Wang N; Shao S; Yang W; Huang L; Liu Y
Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31409011
[TBL] [Abstract][Full Text] [Related]
59. [Hirudin inhibition of human thrombin activity].
Ascenzi P; Bolognesi M; Coletta M; Menegatti E; Amiconi G
Medicina (Firenze); 1990; 10(4):391-2. PubMed ID: 2099980
[TBL] [Abstract][Full Text] [Related]
60. Plasminogen assay by means of the lysis time method.
Berg W; Korsan-Bengtsen K; Ygge J
Thromb Diath Haemorrh; 1965 Sep; 14(1-2):127-44. PubMed ID: 16955971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
